日期:2022.04.29
p53蛋白免疫组织化学检测和TP53 基因突变检测一致性大于92%
基于分子分型,可对患者进行预后风险评估和指导辅助治疗
◆ 和ProMisE研究、Trans-PORTEC研究、TCGA一致的分子检测合理可信比例:华妍安®超过500例子宫内膜癌患者检测统计结果显示, POLE mut型 (8.19%)、MMRd型 (24.23%)、p53 abn (10.58%)、NSMP (56.51%);
华大基因全新升级子宫内膜癌精准诊疗基因检测产品华妍安®,贴合该共识推荐的分型路径,可以通过一次检测实现遗传评估、预后提示及精准用药指导。未来华大将继续发挥自身技术优势,结合临床病理的常规检测,共同推动子宫内膜癌分子分型临床应用的落地,携手共助“天下无癌”美好愿望早日实现!
参考文献:
1.Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-424.
2.Sun, P., et al., Distinct clinical and genetic mutation characteristics in sporadic and Lynch syndrome-associated endometrial cancer in a Chinese population. Cancer Epidemiol, 2021. 73: p. 101934.
3.Lu, K.H. and R.R. Broaddus, Endometrial Cancer. N Engl J Med, 2020. 383(21): p. 2053-2064.
4.Colombo, N., et al., ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol, 2016. 27(1): p. 16-41.
5.Bokhman, J.V., Two pathogenetic types of endometrial carcinoma. Gynecol Oncol, 1983. 15(1): p. 10-7.
6.Cancer Genome Atlas Research, N., et al., Integrated genomic characterization of endometrial carcinoma. Nature, 2013. 497(7447): p. 67-73.
7.Talhouk, A., et al., A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer, 2015. 113(2): p. 299-310.
8.Stelloo, E., et al., Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res, 2016. 22(16): p. 4215-24.
9.Concin, N., et al., ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Arch, 2021. 478(2): p. 153-190.
10. Jessica NM, Derek SC. Remi AN,et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. Cancer, 2021 Jul 15;127(14):2409-2422
11. Nicole Concin, Carien L Creutzberg, Ignace Vergote, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma,Virchows Arch. 2021 Feb;478(2):153-190. doi: 10.1007/s00428-020-03007-z
12. Cancer Genome Atlas Research Network; Integrated genomic characterization of endometrial carcinoma, Nature. 2013 May 2;497(7447):67-73. doi: 10.1038/nature12113.
13. Chung YS, Woo HY, et al, Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer, Am J Obstet Gynecol. 2021 Apr;224(4):370.e1-370.e13
14. Alicia L C, Stephanie M B, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of Clinical Oncology ,2020,38(29):3388-3397
15. 《子宫内膜癌分子检测中国专家共识》2021年版